Capricor Therapeutics forges ahead with FDA on Duchenne drug, despite political tumult
While there have been reports from drugmakers about possible interruptions with FDA matters due to staff layoffs, one company “hasn’t noticed any difference.”
Related Articles
Novo Nordisk strikes telehealth deals for obesity drug, following Eli Lilly
Novo is expanding its direct-to-consumer efforts around its obesity drug Wegovy, partnering with telehealth companies
The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position
With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from
How RFK Jr.’s vaccine criticism is taking hold at the FDA
FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.
How RFK Jr.’s vaccine criticism is taking hold at the FDA
FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.
Amid FDA chaos, approval of a rare disease drug gets delayed — again
Stealth BioTherapeutics had expected the FDA to respond on Tuesday to its marketing application for elamipretide to treat Barth syndrome.
With one month to go, few details on RFK Jr.’s MAHA commission
With a May 24 deadline looming, Kennedy’s MAHA commission has held just one full meeting on its goal of reducing childhood chronic disease.
Medicare regulations hamper providers without helping patients
Many Medicare quality measures are only loosely related to actual patient outcomes. It’s time to deregulate the system, writes Emory professor David Howard.
The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position
With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from
Pharma’s reputation with patient groups dips again, mostly due to pricing issues
For the second consecutive year, the pharma industry saw its reputation dip among patient advocacy groups, largely due to ongoing concerns over pricing issues.
U.S. government researchers present ‘phenomenal’ new data on HPV vaccines
A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two —…
